Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies David J. StewartM. Christine CrippsM. Christine Cripps ORIGINAL ARTICLE Pages: 1 - 8
In vitro metabolism by mouse and human liver preparations of halomon, an antitumor halogenated monoterpene Merrill J. EgorinD. Marc RosenJulie L. Eiseman ORIGINAL ARTICLE Pages: 9 - 14
Mitotic index in the subrenal capsule assay as an indicator of the chemosensitivity of ovarian cancer E. SuonioP. LipponenL. Tuomisto ORIGINAL ARTICLE Pages: 15 - 21
Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues Garth PowisAlfred GallegosJohn Worzalla ORIGINAL ARTICLE Pages: 22 - 28
Comparative disposition of the antineoplastic agent 9-nitrocamptothecin and the inactive isomer 12-nitro camptothecin in CASE-bearing nude mice: effect of route of administration on tissue distribution Ahmed E. AhmedSam JacobJohn S. Stehlin Jr ORIGINAL ARTICLE Pages: 29 - 36
Assessment of microtubule stabilizers by semiautomated in vitro microtubule protein polymerization and mitotic block assays Narima M. LopesHerbert P. MillerBijoy K. Bhuyan ORIGINAL ARTICLE Pages: 37 - 47
Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag / Rij rats Jan H. M. SchellensWim Van de VrieAlexander M. M. Eggermont ORIGINAL ARTICLE Pages: 48 - 52
Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer Paul E. GossSheldon FineKathleen I. Pritchard ORIGINAL ARTICLE Pages: 53 - 60
Diversity of metallothionein content and subcellular localization in the National Cancer Institute tumor panel Elizabeth S. WooAnne MonksJohn S. Lazo ORIGINAL ARTICLE Pages: 61 - 68
Pharmacologic effects of paclitaxel in human bladder tumors Jessie L.-S. AuJohn KalnsM. Guillaume Wientjes ORIGINAL ARTICLE Pages: 69 - 74
Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study D. R. GandaraMartin J. EdelmanRobert B. Livingston ORIGINAL ARTICLE Pages: 75 - 78
Selective inhibition of oncogenic ras-p21 in vivo by agents that block its interaction with jun-N-kinase (JNK) and jun proteins. Implications for the design of selective chemotherapeutic agents Shazia AmarAlbert GlozmanMatthew R. Pincus ORIGINAL ARTICLE Pages: 79 - 85
Phase I study of vinorelbine and paclitaxel in small-cell lung cancer Rosario Vincenzo IaffaioliGaetano FacchiniRosario Vincenzo Iaffaioli CLINICAL TRIAL REPORT Pages: 86 - 90